MISC

2014年2月

Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
  • Hiroshi Matsushita
  • Fusao Ikeda
  • Yoshiaki Iwasaki
  • Hiroyuki Seki
  • Shintaro Nanba
  • Yasuto Takeuchi
  • Yuki Moritou
  • Tetsuya Yasunaka
  • Hideki Onishi
  • Yasuhiro Miyake
  • Akinobu Takaki
  • Kazuhiro Nouso
  • Kazuhide Yamamoto
  • 全て表示

29
2
開始ページ
337
終了ページ
343
記述言語
英語
掲載種別
DOI
10.1111/jgh.12337
出版者・発行元
WILEY-BLACKWELL

Background and Aim: Chronic infection with hepatitis C virus (HCV) decreases health-related quality of life (HRQOL). The present study was planned to investigate the impact of HRQOL of patients with chronic hepatitis C (CHC) on the outcomes of therapy with pegylated interferon and ribavirin (RBV), in addition to IL28B polymorphisms.
Methods: The present study enrolled 228 CHC patients and assessed their HRQOLs prospectively with the 36-item short-form health survey.
Results: The patients with CHC have lower physical HRQOL status than the general population (P = 0.037, the Z-test). The patients with advanced liver diseases exhibited further decreases in HRQOL (P = 0.036, Spearman's rank correlation coefficient). The score of total HRQOL was significantly lower in the group with sustained virological response (SVR) to the therapy with pegylated interferon and RBV than the non-SVR group (P = 0.031, the Mann-Whitney U-test), with significantly lower scores of mental component and its comprising subscales in the SVR group. Stepwise multivariate logistic regression analysis showed that low HRQOL score <= 400 points was significantly associated with SVR (odds ratio = 2.4, P = 0.013), independently from high platelet counts, low HCV RNA, favorable single-nucleotide polymorphism type of IL28B, and HCV serotype 2. The patients with low HRQOL score will have significantly less decrease in HRQOL score by 4 weeks of the treatment than those with high HRQOL score at baseline (P = 0.0045).
Conclusion: HRQOL is one of the significant predictor of the outcomes of therapy with pegylated interferon and RBV independently from IL28B polymorphism.

リンク情報
DOI
https://doi.org/10.1111/jgh.12337
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000336252400020&DestApp=WOS_CPL
ID情報
  • DOI : 10.1111/jgh.12337
  • ISSN : 0815-9319
  • eISSN : 1440-1746
  • Web of Science ID : WOS:000336252400020

エクスポート
BibTeX RIS